"It's very traumatic. It's very triggering. It's just a lot of emotions," says Seven News presenter who reveals a diagnosis was made in December.

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

Five-year survival rates are among the lowest of all cancers, at about 25%. But when caught early enough – through annual CT screenings for those eligible – the disease can be completely curable.

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, M.D ...

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...

Researchers looked for incidence of multiple types of cancer in 417,984 Australian women who used medically assisted reproduction from 1991 to 2018.

Researchers have found hundreds of metabolic enzymes attached to human DNA inside the cell nucleus. Different tissues and cancers show unique patterns of these enzymes, forming a “nuclear metabolic ...

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

Taryne A. Imai, MD, found herself at a professional crossroads in 2022. She had been working for seven years as a thoracic surgeon, most recently as Clinical Chief of Thoracic Surgery at Cedars-Sinai ...

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.